The objective of the impulse programme Swiss Innovation Power was to stimulate the innovation activities, to maintain the innovative strength and secure the long-term competitiveness of small to medium-sized companies in Switzerland in view of the current Covid-19 pandemic.
The Federal Funding Programme for COVID-19 Medicines supports innovative pharmaceutical projects that make a contribution to the secure and rapid supply of COVID-19 medicines. The medicines should be available to the Swiss population by the end of 2022.
